Article

Bbarrons.com on 2021-04-12 22:33

Neurology Drug Study Does Little for Sage Therapeutics, or Its Partner Biogen

A drug under development by Sage and Biogen to treat the shaking disorder called essential tremor delivered mixed results in a Phase 2 study.

Phase 2

Related news

Does Sage Therapeutics' Failure Predict Its Future Results?Forbes
FDA Approves Sage Therapeutics’ Zulresso wsj.com
BSage Therapeutics Stock Collapsed Thursday. Analysts Say It Has Fallen Enough.barrons.com
Phase 2
CRISPR startup Scribe Therapeutics lands big Biogen deal bizjournals.com
Biogen Forbes
WAlzheimer's drug from Biogen, partner receives FDA approval wraltechwire.com
Cambridge , Japan
MDenali Therapeutics stock rockets into record territory after Biogen investment and collaboration marketwatch.com
BHow Sage Therapeutics Beaten-Down Stock Could Come Back2 min read barrons.com
Como
The Petri Dish: Sage, Biogen plan drug application; TV show gets FDA nod bizjournals.com
Why does Biogen need a sixth drug for multiple sclerosis?bizjournals.com
Biogen jumps into psychiatric drug space, forges $3.1B deal with neighbor Sage bizjournals.com
BSage Gets $3 Billion Endorsement of Its Depression Drugs From Biogen barrons.com
Shkin
Tremor drug by Sage, Biogen succeeds in trial, but investors question safety bizjournals.com
MShares of Sage Therapeutics up on Zulresso approval, but analysts expect a slow rollout marketwatch.com
Wall Street
Sage Therapeutics gains $220M in value as depression drug clears trial hurdle bizjournals.com
Phase 2 , Kendall Square , Cambridge
BWhat to Watch at the Alzheimer's Conference (Besides Lilly): Biogen and Prothena barrons.com
Pasadena , Phase 2
Newest FDA approval could boost Partner Therapeutics' Lynnwood plant bizjournals.com
Lynnwood
Top former Alnylam exec Barry Greene named CEO of Sage Therapeutics bizjournals.com
Sage Therapeutics Takes Investors On A Wild Ride As CEO Talks Up Brain Drugs Forbes